Drugs like Ozempic and Wegovy could significantly cut dementia risk

It can reduce diabetes and weight loss treatments such as Ozmpic and Wegovy, known as the GLP-1 stimulants, significantly from the risk of developing any kind of DifferenceAccording to a twin analysis of 26 clinical trials with more than 160,000 participants.

Treatments, which include drugs such as Smaglutide, Liraglutide and Exenatide, have been linked a little bit Decreased dementia risk beforeBut this was dependent on monitoring studies health Records.

now, Katriona Redin At the University of Galwai in Ireland and its colleagues, the results of random experiences were collected, as a group of GLP-1 drugs were given to people with type 2. Diabetic Which has not yet been diagnosed with dementia or cognitive weakness, was tested against the imaginary medicine. They found that taking these medications seemed to significantly reduce the risk of dementia or cognitive weakness during the lower follow -up periods for a period of six months.

“The gold standard will be a great random experience to answer this question, but this definitely adds another stream of evidence [to past studies]He says Next Ziad At the University of Washington University in St. Louis, Missouri, who has not participated in this research.

Diabetes may be DementiaTherefore, it was suggested that the mere control of blood sugar levels results in this preventive effect. For example, a Ticket by Jingshuan Qawah At the University of Florida and its colleagues, her colleagues indicate that a group of diabetes medications called SGLT2 inhibitors, which are less than blood sugar levels by helping the kidneys may reduce the risk of developing Alzheimer’s disease or relevant dementia, based on people’s health records.

But in the analysis controlled by the Reddin team and its team, the Sglt2 inhibitors were not linked to the low risk of dementia, indicating that the preventive effects of the GLP-1 Drugs Exaggeration of mere control of sugar in the blood.

Although the precise mechanism is unclear, these drugs have been linked to low inflammation, with Neuropathy It is increasingly recognized as a cause of dementia. By reducing chronic inflammation, they may be Surprisingly cell death in the brainRedin says.

It may protect GLP-1 medicines as well Cardiovascular problemslike Plaque accumulation In the arteries and High blood pressureWhich can cause dementia.

“It seems that all roads lead to Rome. We can see from multiple monitoring studies and now an analysis of fake studies that these drugs have this [anti-dementia] Impact, “says al -aly.

Al-Aly emphasizes that we are not yet in a place where a person will be described at the risk of increasing the GLP-1 dementia to reduce his possibilities. But he also says that doctors may consider providing these medications on other drugs that reduce glucose for people with type 2 diabetes who are also at risk of cognitive decline, for example if they have a family history in this case. “This research will increase the doctor’s tendency to prescribe these medications,” he says.

Reddin notes that the follow -up period of at least six months was relatively short, and she says, “Large experiments must be done to study the effect of treatment to reduce glucose specifically on dementia and cognitive decrease.” Two clinical experiences achieve As a treatment for early Alzheimer’s disease, it is expected to conclude this year.